Table 1 Characteristics of study cohort by the use of clarithromycin
Variable | Propensity score-matched patients with stable CHD–PUD (n = 8140) | p value | |
|---|---|---|---|
Clarithromycin users | Nonusers | ||
(n = 4070) N (%) | (n = 4070) N (%) | ||
Sex | Â | Â | 0.07 |
 Men | 2008 (49.3) | 1926 (47.3) |  |
 Women | 2062 (50.7) | 2144 (52.7) |  |
Age (year) | Â | Â | 0.79 |
 18–49 | 1263 (31.0) | 1289 (31.7) |  |
 50–59 | 1289 (31.7) | 1248 (30.7) |  |
 60–69 | 889 (21.8) | 892 (21.9) |  |
 ≥ 70 | 629 (15.5) | 641 (15.8) |  |
 Mean (± SD) | 55.8 ± 12.8 | 55.5 ± 13.9 | 0.46 |
Comorbidity | Â | Â | Â |
 Diabetes | 703 (17.3) | 603 (14.8) | 0.003 |
 Hypertension | 1812 (44.5) | 1724 (42.4) | 0.049 |
 COPD | 723 (17.8) | 679 (16.7) | 0.20 |
Charlson comorbidity index (mean ± SD) | 1.0 ± 1.5 | 1.0 ± 1.6 | 0.08 |
No. of medical visits | Â | Â | 0.82 |
 1–12 | 1349 (33.1) | 1374 (33.8) |  |
 13–24 | 1343 (33.0) | 1339 (32.9) |  |
 ≥ 25 | 1378 (33.9) | 1357 (33.3) |  |
Confounding drugs | Â | Â | Â |
 ACEI/ARB | 956 (23.5) | 900 (22.1) | 0.14 |
 Aspirin | 1253 (30.8) | 1141 (28.0) | 0.006 |
 Statins | 499 (12.3) | 466 (11.5) | 0.26 |
 Ticlopidine | 23 (0.6) | 26 (0.6) | 0.67 |
 Calcium channel blockers | 1483 (36.4) | 1458 (35.8) | 0.56 |
 Beta blockers | 841 (20.7) | 793 (19.5) | 0.18 |
 Diuretics | 1903 (46.8) | 1823 (44.8) | 0.08 |
 Antiarrhythmics | 1068 (26.2) | 1059 (26.0) | 0.82 |
 Digoxin | 81 (2.0) | 79 (1.9) | 0.87 |
 Nitrates | 847 (20.8) | 802 (19.7) | 0.21 |